Retatrutide vs Semaglutide: Triple Agonist vs GLP-1 Compared
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-13
An investigational triple-hormone drug vs an FDA-approved single agonist — what the trial data actually shows
Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon receptors) still in Phase 3 trials, while semaglutide (Ozempic, Wegovy) is FDA-approved and activates only the GLP-1 receptor. Early trial data shows retatrutide producing greater average weight loss than semaglutide, but it is not yet approved or available by prescription.
This article is for informational purposes only and is not medical advice. Retatrutide is not yet FDA-approved and is not available by prescription in the US as of this writing. Consult a physician before starting, stopping, or switching any prescription medication.
Retatrutide and Novo Nordisk's semaglutide (sold as Ozempic and Wegovy) both belong to the incretin drug class reshaping obesity and diabetes treatment, but they work through a different number of hormone receptors. Semaglutide activates one — GLP-1. Retatrutide activates three — GLP-1, GIP, and glucagon. That third receptor is the reason retatrutide has produced the largest average weight loss of any incretin drug tested in a Phase 2 trial so far. For the already-approved triple-vs-dual question, see our retatrutide vs tirzepatide comparison, and for the FDA-approved dual-agonist option, see tirzepatide vs semaglutide.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →Retatrutide vs Semaglutide at a Glance
Retatrutide's third receptor (glucagon) is believed to add an energy-expenditure effect on top of the appetite suppression both drugs share, which may explain its larger trial effect size. The table compares the two on the dimensions that matter most before a prescribing decision is even possible.| Dimension | Retatrutide | Semaglutide |
|---|---|---|
| Regulatory status | Investigational — Phase 3 trials ongoing, not FDA-approved | FDA-approved (Ozempic for diabetes, Wegovy for weight management) |
| Mechanism | Triple agonist: GLP-1 + GIP + glucagon receptors | Single agonist: GLP-1 receptor only |
| Avg. weight loss (trials) | ~24% at 48 weeks, highest dose (Phase 2, non-diabetic adults) | ~15% at 68 weeks, highest dose (STEP-1) |
| Developer | Eli Lilly | Novo Nordisk |
| Dosing (trials) | Weekly injection; up to 12 mg | Weekly injection; 0.25-2.4 mg (Wegovy) |
| Availability | Not available by prescription; only through clinical trials | Widely available by prescription (subject to supply/insurance) |
| Cardiovascular outcome data | Not yet established (trials ongoing) | Established (SELECT trial, 2023) |
| Main side effects | Both: nausea, diarrhea, vomiting, constipation (worst during dose titration) | |
Why Does Retatrutide Produce More Weight Loss?
Retatrutide activates a third hormone receptor that semaglutide does not touch: the glucagon receptor. Glucagon receptor activation is thought to increase energy expenditure, adding a metabolic-rate effect on top of the appetite suppression both drugs share through GLP-1. In a Phase 2 trial published in the New England Journal of Medicine, participants without diabetes lost an average of about 24% of body weight at 48 weeks on the highest retatrutide dose — a larger effect than any GLP-1-only or dual-agonist drug has shown in a comparable trial window.
These numbers come from a mid-stage trial with a smaller, more closely monitored patient group than the large Phase 3 programs behind semaglutide's approval. Phase 3 results, which determine real-world approval and labeling, are still pending as of 2026.
Is Retatrutide Available Now?
No. Retatrutide is not FDA-approved and is not legally available by prescription in the US. It can only be accessed through enrollment in an active clinical trial. Any product marketed online as "retatrutide" outside of a trial is an unregulated research chemical with no verified purity, dosing accuracy, or safety oversight — a meaningfully different risk profile than a pharmacy-dispensed, FDA-approved drug like semaglutide.
Semaglutide, by contrast, is widely available today through a licensed prescriber and pharmacy, with established manufacturing standards and a multi-year safety record. For a currently available, more effective alternative to semaglutide, see tirzepatide vs semaglutide, which compares an already-approved dual agonist instead.
Side Effects: What Trial Data Shows
Both drugs produce the same core gastrointestinal side effects seen across the incretin drug class — nausea, diarrhea, vomiting, and constipation — most pronounced during dose escalation. Retatrutide's Phase 2 trial reported a similar overall discontinuation rate for side effects as GLP-1-only and dual-agonist trials, though the smaller trial size means the confidence interval around that estimate is wider than for semaglutide's much larger Phase 3 safety database.
The Bottom Line: What Should You Consider Today?
Since retatrutide isn't available outside a clinical trial, this isn't really a same-day choice — it's a look at what may come next:
- Available today, FDA-approved, prescribable: semaglutide (Ozempic, Wegovy) — the practical choice for anyone starting treatment now.
- Potentially more effective, not yet approved: retatrutide — watch for Phase 3 results and, if approved, an FDA label and pharmacy availability likely years out from full labeling completion.
- Want the largest effect available now: consider tirzepatide, the dual agonist already on the market with a larger average effect than semaglutide alone.
Take the free assessment to see which metabolic factors matter most for you before discussing any GLP-1-class drug with a prescriber.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is retatrutide better than semaglutide?
In early trial data, retatrutide produced greater average weight loss than semaglutide — about 24% versus roughly 15% at the highest doses tested. But retatrutide is still investigational and not FDA-approved, so it isn't a real prescribing option yet, while semaglutide is proven, approved, and available.
Can I get a prescription for retatrutide?
No. Retatrutide is not FDA-approved and cannot be legally prescribed outside of a clinical trial. Products sold online as retatrutide are unregulated research chemicals without verified purity or dosing accuracy.
What is the difference between retatrutide and semaglutide?
Semaglutide activates one hormone receptor (GLP-1). Retatrutide activates three (GLP-1, GIP, and glucagon). The extra glucagon-receptor activity is believed to add an energy-expenditure effect, which is the leading explanation for retatrutide's larger weight-loss results in trials so far.
When will retatrutide be approved?
As of 2026, retatrutide is in Phase 3 trials, the stage required before an FDA approval decision. Drug approval timelines vary, but Phase 3 completion, FDA review, and potential approval typically take at least one to two additional years from mid-stage trial results.
Is retatrutide the same as tirzepatide?
No. Tirzepatide (Mounjaro, Zepbound) is a dual agonist activating GLP-1 and GIP receptors and is already FDA-approved. Retatrutide adds a third receptor (glucagon) and remains investigational. See our retatrutide vs tirzepatide comparison for the full breakdown.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Semaglutide vs Tirzepatide vs Retatrutide: Single, Dual, and Triple Hormone Agonists Compared
Semaglutide vs tirzepatide vs retatrutide: single, dual, and triple hormone agonists compared side by side.
-
Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Compared
Retatrutide vs tirzepatide: investigational triple agonist vs FDA-approved dual agonist.
-
Retatrutide Peptide: Triple Agonist Weight-loss Research, Risks, and Status
Retatrutide peptide research: triple agonist mechanism, trial results, risks, and current availability.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.